- P-ISSN 1225-0163
- E-ISSN 2288-8985
폐암은 전 세계적으로 높은 사망률 때문에 죽음에 이르게 되는 암이다. 폐암은 소세포암과 비소 세포암 두 종류로 나누어 지는데 비소세포암 환자에게서 EGFR 돌연변이가 발견되었고 이 EGFR 돌연변이는 방사선치료와 EGFR tyrosin kinase의 저해제인 gefitinib과 erlotinib의 반응에도 연관되어진다. 이와 같이 EGFR 돌연변이의 검출은 효과적인 치료방법을 제시해 줄 수 있을 것이다. 본 연구에서는 간단하고 값이 싸며, 반응시간이 더 빠르게 유전자 다형성을 검출 할 수 있는 칩-기반 등온증폭반응을 수행하였다. 그 결과, 이 등온증폭 방법은 빠른 증폭 시간과 높은 민감성, 특이성을 가지고 있었으며 현증 검증에서 EGFR 돌연변이를 빠르고 정확하게 진단할 수 있는 유용한 방법이 될 것이다.
Lung cancer is the main cancer on the world today, due to the high case fatality. Lung cancer can devide into two major types, such as small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Mutations in the epidermal growth factor receptor (EGFR) have been described in patients with advanced NSCLC. Mutations in the EGFR are associated with clinical and radiographic responses to EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Thus, the detection of EGFR mutation can offer an effective information in clinical decision-making. In this study, We developed very simple, cheep and rapid mutation detection system by chip-based isothermal amplification method. The method described here has shown the advantages of rapid amplification, high sensitivity, and specificity. Also, it will be useful for rapid and reliable clinical diagnosis of EGFR mutation.
1. A. Jemal, K. C. Chu and R. E. Tarone, Recent trends in lung cancer mortality in the United States. J. Natl. Cancer., Inst. 93, 277-283(2001).
2. D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, Global cancer statistics, CA Cancer. J. Clin., 55, 74-108(2005).
3. S. V. Sharma, D. W. Bell, J. Settleman and D. A. Haber, Nat. Rev. Cancer. 7, 169-181(2007).
4. A. Kurup and N. H. Hanna, Crit Rev Oncol Hematol, 52(2), 117-126(2004).
5. A. Spira and D.S. Ettinger, N. Engl. J. Med. 350, 379- 392(2004).
6. J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu and D. H. Johnson, N. Engl. J. Med., 346, 92-8(2002).
7. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatual, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Chrisriani, J. Settleman and D. A. Haber, N. Engl. J. Med., 350, 2129-39(2004).
8. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris and H. Proc. Natl. Acad. Sci. USA, 101, 13306-11(2004).
9. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J. A. Roth, J. Herz, J. D. Minna and A. F. Gazdar, J. Natl. Cancer., Inst. 97,339-46(2005).
10. S. F. Huang, H. P. Liu, L. H. Li, Y. C. Ku, Y. N. Fu, H. Y. Tsai, Y. T. Chen, Y. F. Lin, W. C. Chang, H. P. Kuo, Y. C. Wu, Y. R. Chen and S. F. Tasi, Clin. Cancer. Res, 10, 8195-203(2004).
11. J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, Johnson BE and Meyerson M, Sci., 304, 1497-500(2004).
12. S. Kobayashi, N. Engl. J. Med., 352, 786-92(2005).
13. Uramoto, H. and Mitsudomi, T. Br. J. Cancer. 96, 857- 863(2007).
14. C. I. Henschke and O. S. Miettinen, Women's susceptibility to tobacco carcinogens, Lung Cancer., 43, 1- 5(2004).
15. P. B. Bach, M. W. Kattan, M. D. Thornquist, M. G. Kris, R. C. Tate and M. J. Barnett, Hsieh L. J. and C. B. Begg, J. Natl. Cancer, Inst. 95, 470-478(2003).
16. Y. M. Coyle, A. T. Minahjuddin, L. S. Hynan, J. D. Minna, J. Thoracic Oncology, 7, 654-61(2006).
17. O. Y. Gorlova, S. F. Weng, Y. Zhang, C. I. Amos, M. R. Spitz, Int. J. Cancer, 121, 111-118(2007).
18. O., Catelinois, A. Logel, D. Laurier, S. Billon, D. Hemon and P. Verger, Environ Health Perspect, 114, 1361-1366(2006).
19. M. Tokumo, S. Toyooka, K. Kiura, H. Shigematsu, K. Tomii, Clinical Cander Res., 11, 1167-1173(2005).
20. T. M. Chin, Diyanah Anuar, Ross Soo and Wei Qi Li, Clinical Chemistry, 53, 62-70(2007).